Notice of Allowance from ARIPO

RNS Number : 1627D

Eden Research plc

25 April 2013

 



Eden Research Plc

("Eden" or "Company")

Notice of Allowance from ARIPO for Plant Bacteria Fungi Formulae

Eden Research plc (AIM: EDEN), the AIM listed agrochemical and encapsulation development company, announces that the African Regional Intellectual Property Organisation (ARIPO) has issued a Notice of Allowance for Plant Bacteria Fungi Formulae (number 004525) to the Company.

This notice relates to formulations of more than one terpene selected from a group of four terpenes. Specific formulations within this definition have proven to be particularly effective for controlling fungal and bacterial plant pathogens.

The ARIPO designated states for this application are the following: Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

Clive Newitt, Managing Director of Eden comments: "We are delighted to announce this Notice of Allowance for Plant Bacteria Fungi Formulae which helps continue to strengthen our intellectual property portfolio. It also helps Eden to further establish its presence in Africa, which is becoming an increasingly significant market in the worldwide food and crop production sector.

Gaining additional patent coverage in the ARIPO region allows our existing, as well as potential, licensees to commercialise products with the protection that a patent provides from competitive threats and ensure that Eden's unique technologies and products can become a viable and valuable part of the industry.

A large amount of the food and other crops (such as cut flowers) produced in Africa are exported to the European supermarkets which means that it is an important market for Eden in which to establish its presence, as it will assist Eden in its endeavours in ensuring that the food we eat has been treated with effective, environmentally-friendly agrochemicals, such as ours."

Enquiries:

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	www.wh-ireland.co.uk
John Wakefield	Tel: [phone]
Walbrook PR Ltd	Tel: [phone]; [e-mail]
Paul McManus (Media Relations)	Mob: [phone] or [e-mail]
Paul Cornelius (Investor Relations)	Mob: [phone] or [e-mail]

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCDMGZDKDMGFZM